Investor News

Recent articles for private investors with a focus on dividend announcements

DividendMax Limited
The Directors of Intu Properties plc have announced an interim dividend per ordinary share (ISIN GB0006834344) of 4.6 pence (2014 - 4.6 pence) payable on 24 November 2015 (see salient dates below).  A scrip dividend alternative will continue to be offered. The dividend may be partly paid as a Property Income Distribution ("PID") and partly paid as a non-PID.  The PID element will be subject to deduction of a 20 per cent withholding tax unless exemptions apply (please refer to the PID special note below).  Any non-PID element will be treated as an ordinary UK company dividend.  For South African shareholders, any non-PID cash dividends may be subject to deduction of South African Dividends Tax at 15 per cent. Shareholders will be advised of the PID/non-PID split no later than Friday 2 October 2015.   Dates The following are the salient dates for the payment of the interim dividend: Thursday, 8 October 2015 Sterling/Rand exchange rate struck. Friday, 9 October 2015 Sterling/Rand exchange rate and dividend amount in SA currency announced. Monday, 19 October 2015 Ordinary shares listed ex-dividend on the JSE, Johannesburg Thursday, 22 October 2015 Ordinary shares listed ex-dividend on the London Stock Exchange. Friday, 23 October 2015 Record date for interim dividend in London and Johannesburg. Friday, 30 October 2015 UK shareholders only: Last date for receipt of Tax Exemption Declaration forms to permit dividends to be paid gross. Tuesday, 24 November 2015 Dividend payment day for shareholders South African shareholders should note that, in accordance with the requirements of Strate, the last day to trade cum-dividend will be Friday, 16 October 2015 and that no dematerialisation or rematerialisation of shares will be possible from Monday, 19 October to Friday, 23 October 2015 inclusive.  No transfers between the UK and South African registers may take place from Wednesday, 7 October to Sunday, 25 October 2015 inclusive.
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
Summary · Group sales +7% CER on a reported basis and +2% CER pro-forma - Pharmaceuticals £3.5 billion, -6% (+2% pro-forma); Vaccines £0.8 billion, +11% (-5% pro-forma); Consumer Healthcare £1.5 billion, +51% (+6% pro-forma) - New Pharmaceutical and Vaccine sales of £446 million in Q2 · Q2 core EPS of 17.3p, flat in CER terms - EPS reflects dilution of Novartis transaction, ongoing pricing pressure partly offset by cost reductions - Integration of new Consumer and Vaccine businesses on track - On track to deliver targeted annual cost savings of £3 billion from all restructuring programmes · Total Q2 EPS of 3.1p and H1 EPS of 170.7p - Reflects phasing of pre-tax transaction gains and accelerated restructuring charges · 2015 earnings guidance and 2016 outlook reiterated - Expect 2015 core EPS to decline at a high teen percentage rate (CER) - 2016 core EPS percentage growth expected to reach double digits (CER) · Q2 dividend of 19p declared - Continued expectation for full year dividend of 80p · R&D innovation with significant potential to drive long-term Group performance - Progress of new respiratory portfolio continues with positive FDA AdCom recommendation for Nucala and regulatory filing for approval in Japan - Positive CHMP decision received for Mosquirix - Group has ~40 NMEs (drugs and vaccines) in Phase II/III clinical development, primarily focused on HIV, Oncology, Vaccines, Cardiovascular, Immuno-inflammation and Respiratory diseases - New data and prospects for advanced/early-stage pipeline to be reviewed at R&D event in November
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited